English 
Español
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región.
Related Articles
-
UDIBI
Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract (Transferon®). SHOW MORE
-
UDIBI
Published: april 10, 2019 CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte...
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
-
UDIBI
Published: march 20, 2021 Consistency of a dialyzable leucocyte extract manufactured at GMPfacilities by Nuclear magnetic resonance spectroscopy More...
-
UDIBI
Published: September 20, 2019 Utilization of naproxen by Amycolatopsis sp. Poz 14 and detectionof the enzymes involved in the...
-
UDIBI
Determination of Peptide Profile Consistency and Safety of Collagen Hydrolysates as Quality Attributes. SHOW MORE
-
UDIBI
Taking advantage of a high-throughput flow cytometer for the implementation of an ADCC assay for regulatory compliance. SHOW MORE
-
UDIBI
Published: September 6, 2022 In Vitro and In Vivo Characterization of a Broadly Neutralizing Anti-SARS-CoV-2 Antibody Isolated from a...
